Turn Therapeutics Inc TTRX 深 沪
交易中 12-24 10:47:45 美东时间
3.025
+0.025
+0.83%
华盛通- 最 高3.03
- 今 开3.03
- 成交量 4264股
- 最 低 2.985
- 昨 收 3.00
- 总市值 8476.90万
- 52周最高 26.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.5701
- 委 比 -50.00%
- 总股本 2802.28万
- 历史最高 26.50
- 量 比 0.40
- 振 幅 1.50%
- 历史最低 2.5701
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Turn Therapeutics Inc. Non-GAAP EPS of -$0.07
Turn Therapeutics Inc. press release (TTRX): Q3 Non-GAAP EPS of -$0.07. Research and Development (R&D) Expenses: Research and development expenses for the three months ended September 30, 2025 were $1...
11-13 23:06
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics' GX-03 technology, targeting IL-36 and IL-31, has been recognized by *Patient Care Online* as a top innovation for atopic dermatitis treatment. This topical agent offers a novel mechanism addressing inflammation behind eczema and psoriasis, potentially reducing reliance on systemics and injectables. The company expects to release lead program data for severe eczema in early 2026. Turn Therapeutics also focuses on advancing wound...
11-11 13:00
Turn Therapeutics signs license deal with surgical product supplier Medline
Turn Therapeutics (TTRX) has signed a global agreement with Medline, a company that supplies medical-surgical products and offers supply chain solutions. The details regarding financial terms, produ...
10-30 21:51
Turn Therapeutics Enters Into Global Supply, Development, And License Agreement With Medline
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global
10-30 19:36
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Turn Therapeutics will host a shareholder webinar on October 22, 2025, at 2:00 PM ET, to discuss execution milestones, pipeline progress, and capital strategy. The company highlights its flexible financing strategy following its direct listing, which preserves early shareholder ownership. Turn has secured an $85 million GEM Global Yield agreement for on-demand capital access. Its phase 2 trial of GX-03 for moderate to severe eczema is progressing...
10-22 12:00
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
Turn Therapeutics has launched a communication initiative including a webinar series and a Founder Blog by CEO Bradley Burnam to engage shareholders and the healthcare community. The blog will share company updates and insights, while the webinar series will discuss ongoing programs and developments, with the first session on October 22, 2025, at 2:00 PM ET. The company, focused on dermatology, wound care, and infectious disease, emphasizes innov...
10-20 12:22
美股牛股 | SEALSQ飙升近40%，与TSS达成合作共同开发安全半导体解决方案；SERV大涨超28%
SEALSQ飙升近40%，与TSS达成合作共同开发安全半导体解决方案；SERV大涨超28%，将与外卖公司DoorDash合作，扩大在美国的业务范围>>
10-10 19:16
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Shares of Richardson Electronics, Ltd. (NASDAQ:RELL) rose sharply in pre-market...
10-09 17:12
PepsiCo, Delta Air Lines And 3 Stocks To Watch Heading Into Thursday
Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges, while Levi Strauss reports after bell.
10-09 14:18
